Identifying rare disease patient populations via integrated claims data
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...
Greg Bell is a panelist during the session titled “Navigating Life Sciences disputes. An arbitrator’s perspective.” For more information on this event, click...
CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as...
Abhishek Kumar, Elaine Damato and Alice Kim present their poster titled “Staying Competitive in a Crowded Vaccines Market: Is There Room for a Third or Fourth...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
